<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35304678</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>26</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>26</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1435-4373</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>41</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
            </PubDate>
          </JournalIssue>
          <Title>European journal of clinical microbiology &amp; infectious diseases : official publication of the European Society of Clinical Microbiology</Title>
          <ISOAbbreviation>Eur J Clin Microbiol Infect Dis</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Campylobacter infection in 4 patients treated with ibrutinib.</ArticleTitle>
        <Pagination>
          <StartPage>849</StartPage>
          <EndPage>852</EndPage>
          <MedlinePgn>849-852</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10096-022-04433-4</ELocationID>
        <Abstract>
          <AbstractText>Ibrutinib is a Bruton tyrosine kinase (BTK) inhibitor used in B-cell lymphoproliferative disorders. Patients with genetic BTK deficiency are susceptible to recurrent and severe Campylobacter infections. We report 4 patients treated with ibrutinib who developed chronic or extra-digestive campylobacteriosis resembling ibrutinib-related adverse events including diarrhea (n = 4), panniculitis (n = 2), and arthritis (n = 1). Microbiological explorations identified Campylobacter jejuni (n = 3) or Campylobacter coli (n = 1). All the patients completely recovered after a short course of oral antibiotic therapy. In patients treated with ibrutinib presenting with chronic diarrhea, dermatological, or rheumatological manifestations, campylobacteriosis should be ruled out before attributing the symptoms to ibrutinib and discuss its discontinuation.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Sorin</LastName>
            <ForeName>Boris</ForeName>
            <Initials>B</Initials>
            <Identifier Source="ORCID">0000-0002-3443-9201</Identifier>
            <AffiliationInfo>
              <Affiliation>Clinical Immunology Department, Hôpital Saint Louis, Paris, France. boris.sorin.aphp@gmail.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Immunology, Saint Louis Hospital, 1 avenue Claude Vellefaux, 75010, Paris, France. boris.sorin.aphp@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vigneron</LastName>
            <ForeName>Julien</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biostatistics and Medical Information, Hôpital Saint Louis, Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fadlallah</LastName>
            <ForeName>Jehane</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Clinical Immunology Department, Hôpital Saint Louis, Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mondesir</LastName>
            <ForeName>Johanna</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Clinical Immunology Department, Hôpital Saint Louis, Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fieschi</LastName>
            <ForeName>Claire</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Clinical Immunology Department, Hôpital Saint Louis, Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Oksenhendler</LastName>
            <ForeName>Eric</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Clinical Immunology Department, Hôpital Saint Louis, Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Galicier</LastName>
            <ForeName>Lionel</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Clinical Immunology Department, Hôpital Saint Louis, Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Malphettes</LastName>
            <ForeName>Marion</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Clinical Immunology Department, Hôpital Saint Louis, Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>18</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Germany</Country>
        <MedlineTA>Eur J Clin Microbiol Infect Dis</MedlineTA>
        <NlmUniqueID>8804297</NlmUniqueID>
        <ISSNLinking>0934-9723</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010880">Piperidines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011720">Pyrazoles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>1X70OSD4VX</RegistryNumber>
          <NameOfSubstance UI="C551803">ibrutinib</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.2</RegistryNumber>
          <NameOfSubstance UI="D000077329">Agammaglobulinaemia Tyrosine Kinase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>JAC85A2161</RegistryNumber>
          <NameOfSubstance UI="D000225">Adenine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000225" MajorTopicYN="N">Adenine</DescriptorName>
          <QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077329" MajorTopicYN="N">Agammaglobulinaemia Tyrosine Kinase</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002169" MajorTopicYN="Y">Campylobacter Infections</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003967" MajorTopicYN="N">Diarrhea</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015451" MajorTopicYN="Y">Leukemia, Lymphocytic, Chronic, B-Cell</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011720" MajorTopicYN="N">Pyrazoles</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011743" MajorTopicYN="N">Pyrimidines</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">B-cell lymphoproliferative disorders</Keyword>
        <Keyword MajorTopicYN="N">Campylobacter sp.</Keyword>
        <Keyword MajorTopicYN="N">Ibrutinib</Keyword>
        <Keyword MajorTopicYN="N">Panniculitis</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>19</Day>
          <Hour>5</Hour>
          <Minute>32</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35304678</ArticleId>
        <ArticleId IdType="doi">10.1007/s10096-022-04433-4</ArticleId>
        <ArticleId IdType="pii">10.1007/s10096-022-04433-4</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Stephens DM, Byrd JC (2019) How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. Blood 133:1298–1307. https://doi.org/10.1182/blood-2018-11-846808</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2018-11-846808</ArticleId>
            <ArticleId IdType="pubmed">30642919</ArticleId>
            <ArticleId IdType="pmc">6428663</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dion J, Malphettes M, Bénéjat L, Mégraud F, Wargnier A, Boutboul D et al (2019) Campylobacter infection in adult patients with primary antibody deficiency. J Allergy Clin Immunol Pract 7:1038-1041.e4. https://doi.org/10.1016/j.jaip.2018.06.014</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaip.2018.06.014</ArticleId>
            <ArticleId IdType="pubmed">29981862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Najjar I, Paluca F, Loukidis K, Tarr PE (2020) Recurrent Campylobacter enteritis in patients with hypogammaglobulinemia: review of the literature. J Clin Med 18:9. https://doi.org/10.3390/jcm9020553</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/jcm9020553</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fernández-Cruz A, Muñoz P, Mohedano R, Valerio M, Marín M, Alcalá L et al (2010) Campylobacter bacteremia: clinical characteristics, incidence, and outcome over 23 years. Medicine (Baltimore) 89:319–330. https://doi.org/10.1097/MD.0b013e3181f2638d</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MD.0b013e3181f2638d</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inoue K, Sasaki S, Yasumi T, Imai K, Kusunoki T, Morio T et al (2020) Helicobacter cinaedi-associated refractory cellulitis in patients with X-linked agammaglobulinemia. J Clin Immunol 40:1132–1137. https://doi.org/10.1007/s10875-020-00830-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10875-020-00830-6</ArticleId>
            <ArticleId IdType="pubmed">32914284</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Degand N, Dautremer J, Pilmis B, Ferroni A, Lanternier F, Bruneau J et al (2017) Helicobacter bilis-associated suppurative cholangitis in a patient with X-linked agammaglobulinemia. J Clin Immunol 37:727–731. https://doi.org/10.1007/s10875-017-0437-z</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10875-017-0437-z</ArticleId>
            <ArticleId IdType="pubmed">28856582</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arai A, Kitano A, Sawabe E, Kanegane H, Miyawaki T, Miura O (2007) Relapsing Campylobacter coli bacteremia with reactive arthritis in a patient with X-linked agammaglobulinemia. Intern Med 46:605–609. https://doi.org/10.2169/internalmedicine.46.6108</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2169/internalmedicine.46.6108</ArticleId>
            <ArticleId IdType="pubmed">17473499</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Autenrieth IB, Schuster V, Ewald J, Harmsen D, Kreth HW (1996) An unusual case of refractory Campylobacter jejuni infection in a patient with X-linked agammaglobulinemia: successful combined therapy with maternal plasma and ciprofloxacin. Clin Infect Dis 23:526–531. https://doi.org/10.1093/clinids/23.2.526</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/clinids/23.2.526</ArticleId>
            <ArticleId IdType="pubmed">8879775</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buss JE, Cresse M, Doyle S, Buchan BW, Craft DW, Young S (2019) Campylobacter culture fails to correctly detect Campylobacter in 30% of positive patient stool specimens compared to non-cultural methods. Eur J Clin Microbiol Infect Dis 38:1087–1093. https://doi.org/10.1007/s10096-019-03499-x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10096-019-03499-x</ArticleId>
            <ArticleId IdType="pubmed">30783889</ArticleId>
            <ArticleId IdType="pmc">6520473</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fabbro SK, Smith SM, Dubovsky JA, Gru AA, Jones JA (2015) Panniculitis in patients undergoing treatment with the Bruton tyrosine kinase inhibitor ibrutinib for lymphoid leukemias. JAMA Oncol 1:684–686. https://doi.org/10.1001/jamaoncol.2015.0457</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaoncol.2015.0457</ArticleId>
            <ArticleId IdType="pubmed">26182170</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singer S, Tan SY, Dewan AK, Davids M, LaCasce AS, Treon SP, et al (2019) Cutaneous eruptions from ibrutinib resembling EGFR inhibitor-induced dermatologic adverse events. J Am Acad Dermatol 20.  https://doi.org/10.1016/j.jaad.2019.12.031</Citation>
        </Reference>
        <Reference>
          <Citation>Stewart J, Bayers S, Vandergriff T (2018) Self-limiting ibrutinib-induced neutrophilic panniculitis. Am J Dermatopathol 40:e28–e29. https://doi.org/10.1097/DAD.0000000000000980</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/DAD.0000000000000980</ArticleId>
            <ArticleId IdType="pubmed">28953011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hammel JA, Roth GM, Ferguson N, Fairley JA (2017) Lower extremity ecchymotic nodules in a patient being treated with ibrutinib for chronic lymphocytic leukemia. JAAD Case Rep 3:178–179. https://doi.org/10.1016/j.jdcr.2017.01.027</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jdcr.2017.01.027</ArticleId>
            <ArticleId IdType="pubmed">28459097</ArticleId>
            <ArticleId IdType="pmc">5396857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P et al (2015) Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med 17(373):2425–2437. https://doi.org/10.1056/NEJMoa1509388</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1509388</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA et al (2013) Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 4(369):32–42. https://doi.org/10.1056/NEJMoa1215637</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1215637</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
